Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...
Company
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...
CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...
Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies
UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...
Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...
Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...
Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101
Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...
Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...
Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...
Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio
Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...
AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...
Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...
AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors
Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...
Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment
The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...
Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort
Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...
Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...
Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...
Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...
Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation
Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...